Viking Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.91B
- P/E (TTM)
- –
- Dividend yield
- –
About Viking Therapeutics
Pharmaceutical Preparations, SIC 2834
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for metabolic and endocrine disorders. Its product pipeline includes VK2735, a dual GLP-1 and GIP receptor agonist being evaluated in subcutaneous and oral formulations for obesity and metabolic conditions. The company is also developing VK2809, an orally available thyroid hormone receptor beta agonist targeting non-alcoholic steatohepatitis, and VK0214, an orally available thyroid hormone receptor beta agonist for X-linked adrenoleukodystrophy. Additionally, its pipeline includes VK5211, a selective androgen receptor modulator studied for recovery following hip fracture surgery, as well as an internally developed dual amylin and calcitonin receptor agonist program.
The company operates in the United States and conducts its research and clinical programs through multi-center trials across various study cohorts. Viking Therapeutics maintains its principal executive offices in San Diego, California.
Summary of the business section of Viking Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Viking Therapeutics, Inc.
- Founded
- 2012
- Headquarters
- San Diego, CA
- Address
- 9920 Pacific Heights Blvd, Suite 500
- Phone
- (858) 704-4660
- Website
- www.vikingtherapeutics.com
- Employees
- 53, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum llp, Costa Mesa, California
Stock & identifiers
- Ticker
- VKTX
- Exchange
- Nasdaq
- IPO date
- Apr 29, 2015
- Shares outstanding
- 117M, Jul 15, 2026
- Public float
- $2.98B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1607678
- CUSIP
- 92686J106
- ISIN
- US92686J1060
- LEI
- 529900IVC72YPFA25M37
- EIN
- 46-1073877
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brian Lian | President & CEO, Director | 2,572,441 |
| Greg Zante | Chief Financial Officer | 212,204 |
| Marianna Mancini | Chief Operating Officer | 422,760 |
| Hubert C. Chen | Chief Medical Officer | – |
| Neil William Aubuchon | Chief Commercial Officer | 4,475 |
| Dorothy Elizabeth Kelly-Gemmell | Director | 6,333 |
| Lawson Macartney | Director | 51,115 |
| Matthew W. Foehr | Director | 132,036 |
| Sarah Kathryn Rouan | Director | 4,390 |
| Charles A. Rowland Jr | Director | 33,150 |
| J. Matthew Singleton | Director | 12,650 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Brian Lian | $21.27M | $7.50M | $5.15M | $625 | $125 |
| FY2024 Brian Lian | $14.30M | $106.75M | $4.69M | $715 | $93 |
| FY2023 Brian Lian | $12.63M | $36.95M | $3.50M | $331 | $94 |
| FY2022 Brian Lian | $5.41M | $13.26M | $1.88M | $167 | $90 |
| FY2021 Brian Lian | $4.06M | $2.81M | $1.43M | $82 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had fifty-three full-time employees, twelve of whom hold a Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 23, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 8, 2021 | Delisting | Notice of delisting from exchange (Form 25) |
| Apr 8, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 29, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 23, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |